Q3 2024 EPS Estimates for The Joint Corp. Decreased by Analyst (NASDAQ:JYNT)

The Joint Corp. (NASDAQ:JYNT) – Roth Capital decreased their Q3 2024 earnings per share (EPS) estimates for shares of Joint in a research report issued to clients and investors on Thursday, May 2nd. Roth Capital analyst G. Kelly now anticipates that the company will earn $0.09 per share for the quarter, down from their prior forecast of $0.10. The consensus estimate for Joint’s current full-year earnings is $0.13 per share. Roth Capital also issued estimates for Joint’s Q4 2024 earnings at $0.16 EPS, Q1 2025 earnings at $0.11 EPS, Q2 2025 earnings at $0.17 EPS and Q4 2025 earnings at $0.24 EPS.

Several other research analysts have also recently commented on the company. StockNews.com raised Joint from a “hold” rating to a “buy” rating in a research report on Monday. B. Riley raised their target price on shares of Joint from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday. TheStreet lowered shares of Joint from a “c-” rating to a “d” rating in a research report on Thursday, March 7th. Finally, Roth Mkm reissued a “buy” rating and issued a $16.00 price objective (up previously from $13.00) on shares of Joint in a research report on Friday, May 3rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Joint has a consensus rating of “Moderate Buy” and a consensus price target of $22.00.

Joint Price Performance

Joint stock opened at $16.13 on Monday. The firm has a 50-day moving average of $12.30 and a 200-day moving average of $10.27. The company has a market cap of $240.98 million, a price-to-earnings ratio of -21.51 and a beta of 1.58. Joint has a one year low of $7.31 and a one year high of $16.39.

Joint (NASDAQ:JYNT) last announced its earnings results on Thursday, March 7th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. Joint had a negative net margin of 9.24% and a positive return on equity of 3.94%. The business had revenue of $30.61 million during the quarter, compared to analysts’ expectations of $29.63 million.

Institutional Investors Weigh In On Joint

Large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP increased its holdings in shares of Joint by 345.0% in the third quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock valued at $37,000 after purchasing an additional 3,233 shares during the last quarter. Barclays PLC raised its holdings in Joint by 29.4% in the 3rd quarter. Barclays PLC now owns 13,725 shares of the company’s stock valued at $123,000 after acquiring an additional 3,119 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in Joint by 43.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock worth $148,000 after acquiring an additional 4,987 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Joint during the third quarter worth approximately $179,000. Finally, Strs Ohio grew its position in shares of Joint by 69.1% in the third quarter. Strs Ohio now owns 25,200 shares of the company’s stock valued at $226,000 after purchasing an additional 10,300 shares during the last quarter. Institutional investors own 76.88% of the company’s stock.

About Joint

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.